Bharat Biotech's Covaxin has tolerable safety, says Lancet study

Bharat Biotech’s Covaxin, which has courted controversy over its restricted use approval despite the lack of efficacy data, has shown tolerable safety outcomes and enhanced immune response in the phase one study, said a paper published in British medical journal Lancet.

Sharing the interim findings, the paper said that the vaccine was well tolerated in all dose groups with no vaccine-related adverse events. The most common adverse event was pain at the injection site, followed by headache, fatigue and fever.

“The overall incidence of solicited local and systemic adverse events in this study was 14–21 per cent in all vaccine-treated groups, which